Data / Drug companies / ViiV Healthcare Company
ViiV Healthcare Company: 26 products in the FDA NDC directory, labeler code 49702
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
ViiV Healthcare Company (labeler code 49702) lists 26 products in the FDA National Drug Code Directory, covering 13 finished drugs by generic name. By type: 26 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on January 21, 2025.
The request: Watch ViiV Healthcare Company (FDA labeler code 49702): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 49702
- Products in commercial distribution
- 26
- Packages
- 28
- Finished drugs by generic name
- 13
- Prescription products
- 26
- Over the counter products
- 0
- Flagged as original packager
- 16 of 16 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 3
- Earliest marketing start
- January 28, 1999
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 26 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 26 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Dolutegravir sodium | 4 | 2 |
| Maraviroc | 3 | 9 |
| Zidovudine | 3 | 4 |
| Cabotegravir and rilpivirine | 3 | 1 |
| Lamivudine | 3 | 14 |
| Abacavir sulfate, dolutegravir sodium, lamivudine | 2 | 1 |
| Cabotegravir | 2 | 1 |
| Abacavir sulfate | 1 | 6 |
| Dolutegravir sodium and rilpivirine hydrochloride | 1 | 1 |
| Lamivudine and zidovudine | 1 | 8 |
| Cabotegravir sodium | 1 | 1 |
| Fostemsavir tromethamine | 1 | 1 |
| Dolutegravir sodium and lamivudine | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 12 | 46.2% |
| Kit | 7 | 26.9% |
| Solution | 3 | 11.5% |
| Capsule | 1 | 3.8% |
| Tablet, film coated, extended release | 1 | 3.8% |
| Tablet, for suspension | 1 | 3.8% |
| Injection, solution | 1 | 3.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Cabenuva | 49702-266 | Kit | New drug applications (NDA) | January 21, 2025 |
| Apretude | 49702-280 | Kit | New drug applications (NDA) | March 31, 2024 |
| Triumeq PD | 49702-258 | Kit | New drug applications (NDA) | March 30, 2022 |
| Apretude | 49702-264 | Kit | New drug applications (NDA) | December 20, 2021 |
| Cabenuva | 49702-253 | Kit | New drug applications (NDA) | January 21, 2021 |
| Vocabria | 49702-248 | Tablet, film coated | New drug applications (NDA) | January 21, 2021 |
| Cabenuva | 49702-240 | Kit | New drug applications (NDA) | January 21, 2021 |
| Selzentry | 49702-260 | Kit | New drug applications (NDA) | October 30, 2020 |
| Rukobia | 49702-250 | Tablet, film coated, extended release | New drug applications (NDA) | July 2, 2020 |
| Tivicay PD | 49702-255 | Tablet, for suspension | New drug applications (NDA) | June 12, 2020 |
| Dovato | 49702-246 | Tablet, film coated | New drug applications (NDA) | April 8, 2019 |
| Juluca | 49702-242 | Tablet, film coated | New drug applications (NDA) | November 21, 2017 |
| Tivicay | 49702-227 | Tablet, film coated | New drug applications (NDA) | June 9, 2016 |
| Tivicay | 49702-226 | Tablet, film coated | New drug applications (NDA) | June 9, 2016 |
| Triumeq | 49702-231 | Tablet, film coated | New drug applications (NDA) | August 22, 2014 |
| Tivicay | 49702-228 | Tablet, film coated | New drug applications (NDA) | August 13, 2013 |
| Selzentry | 49702-224 | Tablet, film coated | New drug applications (NDA) | May 16, 2011 |
| Selzentry | 49702-223 | Tablet, film coated | New drug applications (NDA) | May 16, 2011 |
| Retrovir | 49702-213 | Injection, solution | New drug applications (NDA) | November 4, 2010 |
| Retrovir | 49702-212 | Solution | New drug applications (NDA) | October 28, 2010 |
| Retrovir | 49702-211 | Capsule | New drug applications (NDA) | October 28, 2010 |
| Combivir | 49702-202 | Tablet, film coated | New drug applications (NDA) | October 19, 2010 |
| Epivir | 49702-205 | Solution | New drug applications (NDA) | October 4, 2010 |
| Epivir | 49702-204 | Tablet, film coated | New drug applications (NDA) | October 4, 2010 |
| Epivir | 49702-203 | Tablet, film coated | New drug applications (NDA) | October 4, 2010 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.